Toxicity Study of CJ-10882, a Type IV Phosphodiesterase Inhibitor: 2 Weeks Repeated Oral Administration in Beagle Dogs |
한정희
(한국화학연구원 부설 안전성평가연구소)
배주현 (한국화학연구원 부설 안전성평가연구소) 김종춘 (한국화학연구원 부설 안전성평가연구소) 김달현 (제일제당 종합기술원 제약연구소) 이근호 (제일제당 종합기술원 제약연구소) 송석범 (제일제당 종합기술원 제약연구소) 차신우 (한국화학연구원 부설 안전성평가연구소) |
1 | Banner K.H. and Page C.P. (1996). Anti-inflammatory effects of theophylline aiid selective phosphodiesterase inhibitors. CIin. Exp. Allergy, 26, 2-9 |
2 | Banner K.H. and Page C.P. (1995). Theophylline and slective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial. Eur. Respir. J., 8, 996-1000 |
3 | Larson J.L., Pino M.V, Geiger L.E. and Simeone C.R. (1996). The toxicity of repeated exposure to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol. Toxicol., 78, 44-49 |
4 | Souncss J.E., Aldous D. and Sargent C. (2000). Immunosup-pressive and anti-inflammatory effects of cydic AMP pho-sphodiesterase (PDE) type 4 inhibitors. Immunopharmaco-logy, 47, 127-162 DOI ScienceOn |
5 | Teixeira M.M., Gristwood R.W., Cooper N. and Hellewell P.G. (1997). Phosphodiesterase (PDE) 4 inhibitors: Anti-inflammatory drugs of the future. Trends Pharmacol. Sci., 18 164-171 DOI |